Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease

William T. Hu, MD, PhD; Harro Seelaar; Keith A. Josephs, MST, MD; David S. Knopman, MD; Bradley F. Boeve, MD; Eric J. Sorenson, MD; Leo McCluskey, MD; Lauren Elman, MD; Helenius J. Schelhaas, MD, PhD; Joseph E. Parisi, MD; Benno Kuesters, MD, PhD; Virginia M.-Y. Lee, PhD; John Q. Trojanowski, MD, PhD; Ronald C. Petersen, MD, PhD; John C. van Swieten, MD; Murray Grossman, MD

Background: Frontotemporal dementia and amyotrophic lateral sclerosis are neurodegenerative diseases associated with TAR DNA-binding protein 43— and ubiquitin-immunoreactive pathologic lesions.

Objective: To determine whether survival is influenced by symptom of onset in patients with frontotemporal dementia and amyotrophic lateral sclerosis.

Design, Setting, and Patients: Retrospective review of patients with both cognitive impairment and motor neuron disease consecutively evaluated at 4 academic medical centers in 2 countries.

Main Outcome Measures: Clinical phenotypes and survival patterns of patients.

Results: A total of 87 patients were identified, including 60 who developed cognitive symptoms first, 19 who developed motor symptoms first, and 8 who had simultaneous onset of cognitive and motor symptoms. Among the 59 deceased patients, we identified 2 distinct subgroups of patients according to survival. Long-term survivors had cognitive onset and delayed emergence of motor symptoms after a long monosymptomatic phase and had significantly longer survival than the typical survivors (mean, 67.5 months vs 28.2 months, respectively; P < .001). Typical survivors can have simultaneous or discrete onset of cognitive and motor symptoms, and the simultaneous-onset patients had shorter survival (mean, 19.2 months) than those with distinct cognitive or motor onset (mean, 28.6 months) (P = .005).

Conclusions: Distinct patterns of survival profiles exist in patients with frontotemporal dementia and motor neuron disease, and overall survival may depend on the relative timing of the emergence of secondary symptoms.

Arch Neurol. 2009;66(11):1359-1364
type of cognitive symptom (behavioral vs motor), and the site of MND onset (bulbar vs limb).

**METHODS**

**DATA COLLECTION**

Patient data were collected from the Cognitive/Dementia Clinics and ALS Clinics at the Mayo Clinic, Rochester, Minnesota; University of Pennsylvania Medical Center, Philadelphia; Erasmus University Medical Center, Rotterdam, the Netherlands; and Radboud University Nijmegen Medical Center, Nijmegen, the Netherlands. The clinical FTD phenotype was determined using consensus criteria for FTD, including both behavioral and language variants. Patients were given the diagnosis of dementia if their cognitive symptoms were sufficiently severe to impair their daily functioning, including interference with interpersonal relationships, job performance, instrumental activities of daily living, or activities of daily living, and if the evaluating clinicians considered the cognitive deficits to be sufficiently severe to cause prominent deficits despite the motor symptoms. Patients were diagnosed with MND if they had clinical and laboratory evidence of upper and/or lower motor neuron dysfunction consistent with the diagnosis of ALS according to revised El Escorial criteria or of PLS or upper motor neuron–dominant MND according to proposed criteria. Patients with PLS were included if there was no family history to suggest hereditary spastic paraparesis or if they transitioned to ALS based on clinical and electrophysiological criteria during the disease course. Only 2 patients (1 each from the Mayo Clinic and Erasmus University Medical Center) were diagnosed with PLS in the setting of cognitive-onset FTD-MND. Throughout the rest of the article, we refer to these patients and patients with ALS collectively as having ALS.

Forty patients from the Mayo Clinic were identified by searching the Mayo Clinic electronic medical record system from January 1, 1998, to December 31, 2007, for patients with FTD-MND, ALS-D, and ALS with cognitive impairment sufficiently severe for dementia who were evaluated at the Dementia Clinic or ALS Clinic. Twenty-three patients were recruited from the University of Pennsylvania Medical Center during prospective evaluation for dementia and MND from January 1, 1998, to July 31, 2008. Patients from the Erasmus University Medical Center and the Radboud University Nijmegen Medical Center were recruited and evaluated prospectively for cognitive impairment and MND from January 1, 1995, to July 31, 2008, and 31 patients were identified as having dementia and MND. Medical records were reviewed for historical information including sex, age at cognitive symptom onset, age at motor symptom onset, age at evaluation, age at last follow-up, age at death (if available), cognitive symptoms, location of initial motor symptoms (bulbar vs limb onset), and neurological examination findings. Patients were included only if they were evaluated by cognitive behavioral neurologists with experience in FTD and/or by MND specialists with expertise in ALS. Patients were excluded if there was insufficient historical information on the cognitive or motor symptom: in 5 patients from the Mayo Clinic and 2 patients from the University of Pennsylvania Medical Center, cognitive symptoms were found incidentally during evaluation for MND or motor symptoms were found incidentally during evaluation for cognitive symptoms without timing or history of symptomatic progression. These patients were older when they eventually presented for evaluation (mean age, 74.3 years; \( P < .001 \)) but were otherwise similar in sex, FTD phenotype, and site of MND onset. To analyze the relative timing of cognitive and motor symptom onset, a normalized timing of cognitive symptom onset relative to motor symptom onset was calculated by assigning a negative or positive value to the absolute period between onset of cognitive symptoms and onset of motor symptoms. This normalized timing was considered negative if cognitive symptoms preceded motor symptoms (cognitive onset) and positive if cognitive symptoms followed motor symptoms (motor onset). Patients were considered to have simultaneous onset if they had concurrent onset of cognitive and motor symptoms.

**STATISTICAL ANALYSIS**

All statistical analyses were performed using SPSS version 12.0 statistical software (SPSS Inc, Chicago, Illinois). Descriptive statistics were used to characterize the entire cohort as well as each clinical subgroup. We used \( t \) test to analyze differences in continuous variables and \( \chi^2 \) test to investigate differences in dichotomous variables (including sex, bulbar vs limb onset, social or executive vs language subtype) between groups. Kaplan-Meier survival analysis was used to compare disease duration in patients with FTD and MND according to onset symptom types. K-means cluster analysis was used to group all patients with FTD and MND into clusters using sex, age at symptom onset, type of onset symptom, duration between symptoms, duration of disease, FTD phenotype (social or executive disorder, language disorder, or both), and MND phenotype (bulbar onset or limb onset). The Davies-Bouldin validity index was used to determine the optimal number of clusters. Cox proportional hazards regression was used to analyze factors associated with survival.

A total of 87 patients were identified as having symptoms of FTD and MND (Table 1). Patients were similar in sex, FTD phenotype, age at onset, age at death, and survival across the 4 sites. Fifty-nine patients (68%) had died, and 20 of the deceased patients (34%) had autopsies confirming TDP-43 pathologic lesions. Nineteen patients had pathologic findings of TDP-ir lesions affecting frontal neocortex, hippocampus, and hypoglossal nuclei and/or anterior horn cells, and 1 previously characterized patient with familial FTD-MND had TDP-ir lesions affecting the hippocampus, hypoglossal nuclei, and anterior horn cells but sparing the frontal neocortex.

In this combined cohort, we analyzed whether survival was associated with the relative timing of cognitive and motor symptom onset. We limited this analysis to the 58 deceased patients after excluding 1 outlier with cognitive onset followed by ALS symptoms. In this deceased cohort, normalized timing of cognitive symptom onset was inversely correlated with survival (\( r = 0.694 \)) (Figure 1): survival was longer as cognitive symptoms appeared earlier relative to motor symptoms. However, cases also appeared to form distinct clusters. K-means cluster analysis was used to identify cluster membership, and an optimal number of 2 clusters was determined by the Davies-Bouldin index. Cluster 1 contained 15 patients who all had FTD as their onset symptom (cognitive onset), and cluster 2 contained 43 patients including both patients with cognitive onset and patients with motor onset. Patients in cluster 1 had significantly longer survival (mean, 67.5 months) than patients with a more typical survival in cluster 2 (mean, 28.2 months) (\( P < .001 \)).
Long-term survivors had delayed emergence of secondary symptoms (mean, 43.0 months) relative to typical survivors (mean, 11.2 months) \( (P<.001) \). The long-term survivors in cluster 1 were significantly more likely to have limb-onset MND than typical survivors (12 of 15 patients [80%] vs 11 of 43 patients [26%], respectively; \( P<.001 \)). Long-term survivors otherwise were similar to typical survivors in age at onset, sex, and FTD phenotype \( (Table 2) \). Only 1 long-term survivor had PLS 8 months before death. Five of the long-term survivors went on to autopsy, and all had TDP-ir pathologic lesions.

We extended the analysis to include patients still living at the last follow-up. Nine patients still living at the last follow-up had similarly long disease duration (mean, 77.1 months; range, 60-119 months) and represented additional long-term survivors. Long-term survivors were more likely to have cognitive onset than typical survivors (22 of 25 patients [88%] vs 37 of 62 patients [60%], respectively; \( P=.02 \)). Among the 62 typical survivors, 17 patients (27%) had motor onset; 8 patients (13%) had simultaneous onset of cognitive and motor symptoms within the same month \( (\chi^2=10.8; P=.004) \). There was no difference in survival between patients who developed cognitive symptoms or motor symptoms first \( (Figure 2) \). However, patients with simultaneous onset had the shortest overall disease duration compared with patients with discrete cognitive or motor onset by Kaplan-Meier analysis (mean, 19.2 vs 28.6 months, respectively; \( P=.005 \)).

To further determine the effect of intersymptom duration on survival, we performed a multivariate Cox proportional hazards regression analysis using all patients.
Table 2. Characteristics of Patients According to Survival Patterns

| Characteristic                          | Typical Survivors | Cognitive Onset or Motor Onset | Long-term Survivors | P Value
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Simultaneous Onset (n=6)</td>
<td>Cognitive Onset or Motor Onset (n=54)</td>
<td>Long-term Survivors (n=25)</td>
<td></td>
</tr>
<tr>
<td>Female, No. (%)</td>
<td>5 (62)</td>
<td>21 (39)</td>
<td>8 (32)</td>
<td>.31</td>
</tr>
<tr>
<td>Died, No. (%)</td>
<td>4 (50)</td>
<td>39 (72)</td>
<td>16 (64)</td>
<td>.40</td>
</tr>
<tr>
<td>Age at onset, mean (SD), y</td>
<td>63.0 (12.9)</td>
<td>58.7 (10.2)</td>
<td>58.5 (10.3)</td>
<td>.28</td>
</tr>
<tr>
<td>Cognitive onset, No. (%)</td>
<td>0</td>
<td>37 (69)</td>
<td>22 (88)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Bulbar onset, No. (%)</td>
<td>5 (63)</td>
<td>34 (63)</td>
<td>7 (28)</td>
<td>.01</td>
</tr>
<tr>
<td>Language-dominant cognitive symptoms, No. (%)</td>
<td>3 (38)</td>
<td>16 (30)</td>
<td>7 (28)</td>
<td>.88</td>
</tr>
<tr>
<td>Overall disease duration, mean (SD), mo</td>
<td>19.2 (6.4)</td>
<td>28.6 (8.8)</td>
<td>69.3 (21.1)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Disease duration until secondary symptom onset, mean (SD), mo</td>
<td>0</td>
<td>12.4 (7.9)</td>
<td>44.5 (21.8)</td>
<td>&lt;.001</td>
</tr>
<tr>
<td>Disease duration after secondary symptom onset, mean (SD), mo</td>
<td>19.2 (6.4)</td>
<td>15.1 (7.4)</td>
<td>24.0 (15.5)</td>
<td>.01</td>
</tr>
</tbody>
</table>

*We used χ² test and 1-way analysis of variance to determine differences between dichotomous and continuous variables, respectively.

This analysis also included age at onset, sex, pattern of symptom onset (cognitive, motor, or simultaneous), and site of motor symptom onset. In the group as a whole, prognosis was better in those with longer intersymptom duration (hazard ratio [HR] = 0.939/month; 95% confidence interval, 0.919-0.959; P < .001) and worse in those with bulbar-onset ALS (HR = 1.751; 95% confidence interval, 1.006-3.050; P = .048). When typical and long-term survivors were analyzed separately, intersymptom duration continued to be a strong predictor of survival within each subgroup (typical survivors: HR = 0.925/month; P < .001; long-term survivors: HR = 0.951/month; P = .003). However, older age at onset (HR = 0.913/year; 95% confidence interval, 0.843-0.988; P = .02) was associated with better prognosis only in the long-term survivors, and there was only a trend that bulbar-onset ALS was associated with worse outcome in the typical survivors (P = .11).

By combining data from 4 referral centers, we report the largest clinical series of patients who developed motor symptoms in the setting of FTD and dementia symptoms in the setting of ALS. In this large cohort, we were able to identify 2 unique subgroups of patients according to survival patterns. In addition to typical survivors, we discovered a group of patients with long-term survival characterized by mostly cognitive onset and delayed emergence of secondary symptoms with limb onset ALS.

In our large cohort, patients with FTD-MND or ALS-D have mean and median survival periods in keeping with previously reported values from smaller clinical11,14 and clinicopathologic13,23 series. We found that the relative timing of secondary symptom onset was a strong predictor of prognosis in our study among both typical and long-term survivors. The timing of secondary symptom onset may thus reflect in part the rate of stage wise disease progression regardless of cognitive or motor onset as progression rate is known to influence survival in ALS.24 Furthermore, survival in long-term survivors was inversely correlated with age at onset. It is not known whether age at onset is associated with prognosis in clinical FTD with TDP-ir pathologic lesions, but an older age at onset is associated with better survival in ALS without dementia.25 Thus, the similarities in prognostic factors between long-term survivors, typical survivors, and patients with typical ALS without dementia offer additional support that they form a clinicopathologic continuum.

The power of the large number of patients included in this study enabled us to identify the long-term survivors. One potential explanation for this distinct subgroup may be the differential anatomical involvement by pathologic lesions. In typical survivors, disease involving TDP-ir changes may be evident throughout prefrontal regions and the pyramidal system. The relative delay in onset between cognitive and motor systems is minimal, and the initial symptom at presentation is proportional to the volume of these regions within the frontal lobe. In contrast to the distributed model of TDP-ir pathologic lesions in typical survivors, long-term survivors may have focal onset of TDP-ir changes in prefrontal regions with subsequent involvement of the pyramidal system only following a long delay. Differences between these 2 groups were not detectable on autopsy as pathologic...
changes were insensitive to the relative timing of regional involvement, but future biomarkers of region-specific involvement of TDP-ir pathologic lesions may provide some indication of biological differences between typical and long-term survivors. Other differences between these groups such as progranulin haplotypes may also account for the longer survival and should be ascertained in future prospective studies of FTLD-MND and ALS-D.

This study has a number of limitations. First, our observations are retrospective in nature. More patients had cognitive onset than motor onset from centers with long-established interests in dementing illnesses, although patients were equally likely to be seen at Cognitive/Dementia or ALS Clinics. Ascertainment bias may account for the longer range of intersymptom durations in cognitive-onset patients as dementia may delay subjective motor complaints; the smaller number of motor-onset patients may also be due in part to the recent recognition of dementia in ALS. Survival data were incomplete in some cases as patients were lost in follow-up. Only a proportion of cases had autopsy confirmation. The combination of FTD and MND nearly always correlated with TDP-ir pathologic lesions, although rare exceptions with a tau-positive disorder have been reported. Lastly, referral bias may exist in that most patients were referred by primary neurologists or primary care providers. However, with the low prevalence of FTD-MND and ALS-D in general clinical practice, this represents the largest multicenter study to date on the clinical features of patients with cognitive and motor TDP-43 involvement. Patients with ALS who have clinical or subclinical cognitive impairment but not dementia are beyond the scope of the current study, although more careful cognitive assessments should be included in future studies so that the severity of cognitive impairment can be correlated with prognosis. With these caveats in mind, we propose 2 groups of patients with combined FTD and ALS: typical survivors and long-term survivors. Survival is influenced by the intersymptom duration between initial and secondary symptoms, the symptom of onset, and the site of ALS onset. Patients with cognitive onset and significantly delayed emergence of motor symptoms should be identified for their atypical prognosis, and patients with simultaneous onset of cognitive and motor symptoms also may have an atypical prognosis. Future studies will be necessary to assess biological factors associated with prolonged disease duration for potential therapeutic strategies.

Accepted for Publication: March 20, 2009.
Correspondence: William T. Hu, MD, PhD, Department of Neurology, University of Pennsylvania School of Medicine, 3400 Spruce St, Philadelphia, PA 19106 (huw@uphs.upenn.edu).


Financial Disclosure: Dr Knopman serves on a data safety monitoring board for Sanofi-Aventis and is an investigator in a clinical trial sponsored by Elan Pharmaceuticals. Dr Boeve is an investigator in a clinical trial sponsored by Myriad Pharmaceuticals. Dr Petersen has been a consultant to GE Healthcare and has served on a data safety monitoring board in a clinical trial sponsored by Elan Pharmaceuticals.

Funding/Support: This work was supported by the American Academy of Neurology Clinical Research Training Fellowship, grant 06-0204 from Princes Beatrix Fonds, grants AG17586, AG15116, and NS44266 from the US Public Health Service, Roadmap Multidisciplinary Clinical Research Career Development Award Grant (K12/NICHD)-HD49078 from the National Institutes of Health, and the Robert H. and Clarice Smith and Abigail Van Buren Alzheimer’s Disease Research Program of the Mayo Foundation.

REFERENCES


**Announcement**

**Trial Registration Required.** In concert with the International Committee of Medical Journal Editors (ICMJE), *Archives of Neurology* will require, as a condition of consideration for publication, registration of all trials in a public trials registry (such as http://ClinicalTrials.gov). Trials must be registered at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after July 1, 2005. The trial registration number should be supplied at the time of submission. For details about this new policy, and for information on how the ICMJE defines a clinical trial, see the editorial by DeAngelis et al in the January issue of *Archives of Dermatology* (2005;141:76-77). Also see the Instructions to Authors on our Web site: www.archneurol.com.